Looking to sell Element Biosciences stock or options?
Element Biosciences is a biotechnology company focused on developing innovative and affordable DNA sequencing technologies. Their platform aims to deliver high-quality genomic data with greater accuracy and flexibility, catering to a wide range of research and clinical applications. Element Biosciences seeks to democratize access to advanced sequencing capabilities, driving progress in genomics and personalized medicine.
Meritech Capital Partners, Samsung Electronics, Fusion Fund, Alexandria Venture Investments, Logos Capital, Foresite Capital, Janus Henderson Investors, JS Capital Management, Wellington Management, Venrock, RA Capital Management, T. Rowe Price Group, Morgan Stanley, Fidelity Management & Research.
Element Biosciences is currently a private company. This means that the company is not listed on any public exchange and so there is no public market for its stock. However, there may still be ways to monetize Element Biosciences stock. Depending on Element Biosciences’s policies, you may be able to: (1) find a private buyer in the secondary market to purchase your stock, (2) borrow against your stock, or (3) exchange Element Biosciences stock into the Collective Exchange Fund for a limited partnership interest and then borrow non-recourse against your interest to generate immediate cash. This last alternative can be much quicker and net you more after-tax cash than your other options. An exchange into our fund also reduces your risk by diversifying your holdings out of an over-concentrated position.
Collective Liquidity can provide liquidity to shareholders of Element Biosciences stock in two ways. First, Element Biosciences employees can exchange shares into the Collective Exchange Fund and then borrow non-recourse to generate immediate cash. This can net you more after-tax cash than a stock sale. It also reduces your risk by diversifying your holdings out of an over-concentrated position. In some cases, Collective may also be able to purchase your Element Biosciences stock. Note that all transactions in Element Biosciences shares are subject to the company’s policies regarding secondary transactions. Schedule a call with a Collective Liquidity representative to learn more about your private market liquidity alternatives.
Element Biosciences stock is not listed on any public exchange and so there is no public market for its shares. Therefore, there is no single, centralized price for Element Biosciences stock. Typically, shares of private companies like Element Biosciences are set with buyers in one off negotiations. Collective Liquidity, however, uses a proprietary algorithm to determine its bids so we almost always have an immediately actionable price for you.
On Jul 2024, Element Biosciences is reported to have closed an equity financing in which the investors valued the company at $1.05B. This valuation is typically calculated by multiplying the per share price of the preferred stock sold in the financing by the number of Element Biosciences shares outstanding assuming the conversion of all stock options, warrants, etc.
Tickers are used to identify company’s shares on public markets like the NYSE or Nasdaq. Because Element Biosciences is not currently publicly traded, it does not have a ticker symbol.
Element Biosciences has not yet conducted an initial public offering (“IPO”) and so remains a private company. Though Element Biosciences is a well-known, successful company, there can be no assurance that it will ever go public or be sold. Because of the risk this imposes on Element Biosciences shareholders, many investors elect to gain liquidity for at least some of their shares before the IPO. Schedule a call with a Collective Liquidity representative to discuss your private market liquidity alternatives.